Completed
PHASE1
INTERVENTIONAL
NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered subcutaneously (SC)
Name:
Metoprolol
Type:
DRUG
Description:
Administered orally
Primary Outcomes
Measure:
Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol
TimeFrame:
Day 1 to Day 3
Description:
PK: AUC (0-∞) of Metoprolol
Measure:
Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide
TimeFrame:
Day 9 to Day 11
Description:
PK: AUC (0-∞) of Metoprolol with Retatrutide
Measure:
PK: Maximum Concentration (Cmax) of Metoprolol
TimeFrame:
Day 1 to Day 3
Description:
PK: Cmax of Metoprolol
Measure:
PK: Cmax of Metoprolol with Retatrutide
TimeFrame:
Day 9 to Day 11
Description:
PK: Cmax of Metoprolol with Retatrutide
Trial Information
NCT ID
NCT06808802
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025